MMRV Use May Reveal Vaccine Access Gaps
Overview
A study of 213,445 children in King County, Washington, found that those receiving the MMRV vaccine were more likely to be from safety-net clinics and participate in the Vaccines for Children program.
Background
The combination measles, mumps, rubella, and varicella vaccine (MMRV) is an important option for childhood immunization, yet its uptake may vary significantly across different demographic groups. This study provides insights into the populations that select MMRV.
Data Highlights
| Vaccine Type | Percentage |
|---|---|
| MMR + VAR | 64% |
| MMR | 18% |
| MMRV | 15% |
| VAR | 4% |
Key Findings
- 64% of children received MMR + VAR as their first vaccination.
- 15% of children received the MMRV vaccine as their first vaccination.
- Children receiving MMRV were more likely to be eligible for the Vaccines for Children program.
- 95% of children completed both measles and varicella vaccine recommendations before age 4.
- MMRV use remained stable throughout the study period.
- Reduced access to MMRV could disproportionately affect VFC-eligible children.
Clinical Implications
Healthcare providers should be aware of the demographic disparities in vaccine access and consider these factors when planning immunization strategies. Ensuring equitable access to combination vaccines like MMRV is essential for timely vaccination and public health.
Conclusion
The study underscores the importance of understanding vaccine access patterns to inform policy decisions and address potential disparities in immunization among vulnerable populations.
Related Resources & Content
- Fagalde MS, et al, JAMA Network Open, 2023 -- MMRV Use May Reveal Vaccine Access Gaps
- Open Forum Infectious Diseases — Limited Vaccination Rates and Health Disparities for Respiratory Syncytial Virus Among Veterans in the United States
- MDSpire News — Study Finds Low RSV Vaccine Uptake Among Older Adults
- the medicine maker — Does the Vaccine Rollout Ensure Equitable Access?
- Measles Vaccine Recommendations | Measles (Rubeola) | CDC
- MMRV Vaccine Safety | Vaccine Safety | CDC
- Vaccines for Children (VFC) Program Eligibility | VFC Program | CDC
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
